TaiRx, Inc.

TaiRx, Inc. is a biotechnology company based in Taipei, Taiwan, specializing in the research, development, and commercialization of therapeutics primarily aimed at cancer treatment. Established in 2011, the company has developed a pipeline featuring advanced-stage assets such as CVM-1118, an oral anti-cancer drug currently in Phase II clinical trials. Its research also extends to other investigational drugs and formulations, including TRX-920 for oral delivery and TRX-105 designed for the treatment of colitis symptoms. Additional products in TaiRx’s portfolio include Zelnite, which addresses selenium deficiency, as well as ongoing development of diagnostic devices and antibody drugs. Operating in the health technology sector, specifically within medical specialties, TaiRx, Inc. targets critical, unmet medical needs, supporting innovation and expansion within Taiwan’s biotechnology industry. The company plays a significant role in advancing oncology and related therapeutic markets in the region, contributing to both scientific progress and healthcare improvement through its ongoing research and clinical programs.